Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 7/20 | 0.59 |
| ▸ | METAP1 | P53582 | 6/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | MTOR | P42345 | 1/20 | 0.59 |
| ▸ | CLK2 | P49760 | 6/20 | 0.55 |
| ▸ | CLK3 | P49761 | 5/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | FLT1 | P17948 | 1/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.52 |
| ▸ | WNT1 | P04628 | 1/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | CBFB | Q13951 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18449892 | 0.88 | CLK2 (0.59) | METAP2METAP1NPC1PKMRAB9A | |
| SCHEMBL18454489 | 0.88 | CLK2 (0.53) | METAP2METAP1NPC1PKMRAB9A | |
| SCHEMBL18438101 | 0.87 | METAP2 (0.62) | METAP2METAP1NPC1PKMRAB9A | |
| SCHEMBL4042304 | 0.85 | FGFR1 (0.63) | METAP2METAP1NPC1PKMRAB9A | |
| SCHEMBL18438773 | 0.84 | CLK2 (0.61) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL18450642 | 0.84 | CLK2 (0.61) | NPC1RAB9ASMN1; SMN2HPGDCLK2 | |
| SCHEMBL18438234 | 0.82 | CLK2 (0.67) | HPGDCLK2CLK3DYRK1AFGFR1 | |
| SCHEMBL18438342 | 0.81 | CLK2 (0.83) | CLK2CLK3DYRK1AFGFR1FLT1 | |
| SCHEMBL18445148 | 0.81 | ITK (0.60) | CLK2CLK3DYRK1ALRRK2CHEK1 | |
| SCHEMBL18439858 | 0.80 | CLK2 (0.65) | CLK2CLK3DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392383-B2 | 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-08-27 | — | — | US | claimed |
| WO-2017023989-A1 | 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | claimed |
| US-10392383-B2 | 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-08-27 | — | — | US | disclosed |
| US-10392383-B2 | 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-08-27 | — | — | US | disclosed |
| WO-2017023989-A1 | 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023989-A1 | 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392383-B2 | 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof | WNT1, WNT3, WNT3A | METAP2 4603/4885METAP1 4362/4885NPC1 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.